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A study recently published in Cancer has revealed a two-stage screening strategy that is highly specific for detecting early-stage ovarian cancer.
The single-arm, prospective study included 4051 postmenopausal women who participated over 11 years and had an annual blood test to track changes in CA125 levels, a known tumor marker in ovarian cancer. Using the Risk of Ovarian Cancer Algorithm, the researchers put the patients into three groups: women who were at low risk would have another test in 1 year; those at intermediate risk would have a repeat test in 3 months; and those at high risk were referred to a gynecologic oncologist to receive a transvaginal ultrasound.
The average annual rate for a repeat test in 3 months was 5.8% and the average annual referral rate to a gynecologic oncologist was 0.9%. Of the high-risk group, ten women underwent surgery; four were found to have invasive ovarian cancers, two had low-malignant-potential tumors, one had endometrial cancer and three had benign ovarian tumors. The four women with invasive ovarian cancer had previously had low-risk annual CA125 test values for at least 3 years, meaning that the cancers were detected at an early stage.
This represents a 40% positive-predictive value (95% CI: 12.2-73.8) for detecting invasive ovarian cancer and the specificity was 99.9% (95% CI: 99.7-100).
"…our findings suggest that using a longitudinal (or change over time) screening strategy may be beneficial…"
"The results from our study are not practice-changing at this time; however, our findings suggest that using a longitudinal (or change over time) screening strategy may be beneficial in postmenopausal women with an average risk of developing ovarian cancer," commented Karen Lu, the lead author of the study from the University of Texas MD Anderson Cancer Center (TX, USA). "We are currently waiting for the results of a larger, randomized study currently being conducted in the UK that uses the same Risk of Ovarian Cancer Algorithm in a similar population of women. If the results of this study are also positive, then this will result in a change in practice." and colleagues presented the worldwide analysis of over 11,000 female patients involved in 26 randomized stent studies. In cardiac stent clinical trials, women have typically been under-represented with just 25% or fewer of the participants being female.
"This study was not undertaken purely because of the lack of female participants," states Usman Baber (Mount Sinai Medical Center); however, whether this has affected how heart disease has been treated in women in comparison to men in the past should be considered.
Three different generations of cardiac stent were included in this ana lysis, all of which were demonstrated to be effective treatments in women. A promising finding was that the newest stent, the drug-eluting stent, was safer in women than the earlier models and correlated with a notable reduction in the need to reopen the artery. Cardiac stent development is therefore progressing in a positive direction and their benefits for women are being confirmed. 
Worldwide analysis confirms the benefits of cardiac stents in women
A new study has confirmed previously published recommendations stating the need for increased mammographic screening in younger women to reduce breast cancer mortality and prolong survival.
Previous trials and meta-analyses of breast cancer screening have demonstrated varying rates of mortality reduction, raising questions about the value of screening and whether or not treatment advances have diminished the importance of early detection. A new analysis published online in the journal Cancer has demonstrated that, despite new therapeutic drugs and protocols for treating breast cancer, regular screening is the most efficient way to further reduce the breast cancer mortality rate.
Using a technique known as 'failure analysis', which looks backwards from death to discover correlations at diagnosis, researchers at Harvard Medical School (MA, USA) followed 7301 patients with invasive breast cancer, diagnosed between 1990 and 1999, until 2007 . Blake Cady (Harvard Medical School) and colleagues analyzed demographics, mammography use, surgical and pathology reports, disease recurrence, and deaths.
The study data suggest that women aged <50 years are the primary group that would receive the greatest benefit from increased cancer screening. The study confirmed that the 20% of the study population who did not receive regular mammograms resulted in 71% of confirmed breast cancer deaths. The majority of those who died from breast cancer had never received a mammogram prior to diagnosis, showing that treatment is not necessarily the primary survival factor. Furthermore, documented breast cancer deaths occurred in 50% of women aged <50 years, compared with 13% of those ≥70 years of age. The median age at diagnosis for those who died of the disease was 49 years of age, but 72 years of age for any other cause of death.
The current CDC recommendations suggest that women aged 40-49 years discuss screening mammograms with their doctor. The importance of undergoing regular screening is only emphasized in those aged >50 years, despite recommendations from the American Cancer Society, American Congress of Obstetricians and Gynecologists, American College of Radiology and Society of Breast Imaging for greater use of mammographic screening in all women aged ≥40 years.
As aggressive tumors are found more frequently in younger women, the study suggests that increasing screening in this age group would be of therapeutic benefit as, although great progress has been made in breast cancer therapeutics, early detection is still an essential factor in increasing survival. "This study should effectively end confusion over when, and particularly if, women need to begin screening," commented Murray Rebner, president of the Society of Breast Imaging (VA, USA). "While these findings cannot bring back those already lost, they clearly demonstrate that mammography saves lives, and many more deaths can be avoided through regular screening."
According to the study, if recommendations are followed, the breast cancer mortality rate could decrease to 5% by 2030. 
Size matters: insight into mental wellbeing and obesity
Reducing the need for surgery in ectopic pregnancy:
is a lung cancer drug the answer?
Obesity is an issue in many countries with approximately 60% of the German population being affected. However, a study published by scientists from the Institute of Health Economics and Health Care Management (IGM; Neuherberg, Germany) and the Institute of Epidemiology II (EPI II; Neuherberg, Germany) reports that, as females' weight increases, their mental well-being actually improves. Being overweight can have a negative impact on an individuals physical health and could lead to many serious issues, including diabetes. However, the effect of weight gain on health-related quality of life has not been clearly established. Rolf Holle and his research team (IGM and EPI II) determined the physical health deteriorations that are associated with weight gain while utilizing health-related quality-oflife scores. In a population-based cohort of over 3000 Germans assessed at baseline and after a 7-year follow-up, the study identified a positive correlation between mental health and BMI in females. Heavy weight gain, classed as ≥10%, was associated with deterioration in physical health but an improvement in mental health by more than three points on the health-related quality-of-life score.
These results could provide important information for future research investigating the best methods to treat and prevent obesity, and give insight into how to tackle whether this should be approached differently in women. Biomarker index that may accurately identify women at long-term risk of breast cancer relapse Researchers, led by Dennis Sgroi (Massachusetts General Hospital Cancer Center, MA, USA), have determined that the breast cancer index (BCI) assay reliably identifies women who are at risk of early and late distant recurrence. The study, published in Lancet Oncology, compares the BCI with other prognostic tests investigating their ability to determine which patients are most likely to suffer relapse in future. The typical treatment for estrogen receptor-positive breast cancer is either an aromatase inhibitor or tamoxifen, over the course of 5 years. Like with many cancers, however, the treatment is not always successful and many women run the risk of relapse in the long term. Being able to identify those women who are more likely to experience breast cancer relapse would Researchers from the University of Edinburgh (UK) and the University of Melbourne (Victoria, Australia) have investigated the use of a lung cancer drug in combination with the conventional treatment methotrexate as an alternative treatment for ectopic pregnancy. Their results, published in the journal Obstetrics & Gynecology, may lead to a reduction in the number of patients who need to undergo surgery.
Ectopic pregnancy can be a stressful experience with both psychological and physical effects and leads to up to 8% of pregnancy-related deaths. Ectopic pregnancy occurs when an embryo incorrectly be beneficial and influence the prolonged treatment patients would receive.
In the current study, the researchers were comparing the BCI assay with an immunohistochemical prognostic model (IHC4) and a 21-gene recurrence score (Oncotype DX, Genomic Health, CA, USA) to investigate which was the most significant prognostic test for both early and late recurrence of breast cancer. Recurrence was studied over a 10-year period in 665 estrogen receptor-positive tissues from patients already involved in the TransATAC clinical trial.
The study concluded that, although all three prognostic tests could predict the chance of relapse in the first 5 years, only the BCI assay accurately determined those with a risk of long-term recurrence. The assay distinguished between the 60% of patients at low risk from the 40% of patients who were at significant risk in the long term.
The results of this study regarding the accuracy of the BCI could be of great importance for the long-term treatment choice for breast cancer, determining who would benefit from extended endocrine therapy or an alternative treatment option. implants in the fallopian tube. During the early stages this can be treated with drugs; however, once more developed, a surgical procedure must be undertaken. The conventional drug treatment, methotrexate, acts by affecting the vitamin folate. The investigators instead prescribed methotrexate alongside a lung cancer drug, gefitinib, which blocks a protein involved in promoting cell growth and exists in particularly high levels at the location of ectopic pregnancy.
This combination, tested in a Phase I, nonrandomized, open-label study of 12 women with ectopic pregnancies, proved to be more effective at curing ectopic pregnancy then methotrexate alone. This was determined by examining human chorionic gonadotrophin decline. In the University of Edinburgh press release, Andrew Horne (University of Edinburgh) comments, "reducing the treatment time for women who do not need surgery would also have a significant impact in reducing the emotional stress of such a diagnosis."
This combined treatment could significantly reduce the need to remove the fallopian tubes and aid the patients' level of fertility. The results of this small, preliminary clinical trial support the need for the implementation of a larger scale study to examine the safety and efficacy of the treatment more closely. Dermatol. doi:10.1001/jamadermatol.2013.5768 (2013) (Epub ahead of print) . A retrospective cohort study in the National Health Service (UK) aimed to investigate whether there were any effects of maternal exposure to topical steroids on adverse outcomes of pregnancy. The study involved over 7000 pregnant women unexposed to topical corticosteroids and over 2500 pregnant women using topical corticosteroids. Adverse outcomes measured included low birth weight, preterm delivery and mode of delivery. The study concluded that there were no associations between most adverse pregnancy outcomes measured and topical corticosteroid use. However, this study, in addition to available evidence, concluded that the risk of low birth weight correlated with the quantity of corticosteroid exposure. Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by  race, weight, and breast density. J. Natl Cancer Inst. 105(18), 1365-1372 (2013) . The positive association between breast cancer risk and hormone replacement therapy (HRT) has been demonstrated in a number of studies. However, patient factors may cause this correlation to vary. In the study of 9300 breast cancer cases in postmenopausal women aged 45 years and over, screening mammograms were examined. Various analyses were utilized in this study, including logistic regression to determine associations between HRT race/ethnicity, age, BMI and breast density. The risk was over 20% greater in white, Hispanic and Asian women who had undergone HRT. Breast cancer risk was also higher in those with a low/normal BMI and very dense breasts; however, no excess risk was seen in those individuals who were overweight/obese. The results of this study could help determine which patients are suited to HRT for menopausal symptom relief.
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